Wolcott-Rallison syndrome: Clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity

Valérie Senée, Krishna M. Vattem, Marc Delépine, Lynn A. Rainbow, Céline Haton, Annick Lecoq, Nick J. Shaw, Jean Jacques Robert, Raoul Rooman, Catherine Diatloff-Zito, Jacques L. Michaud, Bassan Bin-Abbas, Doris Taha, Bernard Zabel, Piergiorgio Franceschini, A. Kemal Topaloglu, G. Mark Lathrop, Timothy G. Barrett, Marc Nicolino, Ronald WekCécile Julier

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Wolcott-RaRison syndrome (WRS) is a rare autosomal-recessive disorder characterized by the association of permanent neonatal or early-infancy insulin-dependent diabetes, multiple epiphyseal dysplasia and growth retardation, and other variable multisystemic clinical manifestations. Based on genetic studies of two inbred families, we previously identified the gene responsible for this disorder as EIF2AK3, the pancreatic eukaryotic initiation factor 2α (eIF2α) kinase. Here, we have studied 12 families with WRS, totalling 18 cases. With the exception of one case, all patients carried EIF2AK3 mutations resulting in truncated or missense versions of the protein. Exclusion of EIF2AK3 mutations in the one patient case was confirmed by both linkage and sequence data. The activities of missense versions of EIF2AK3 were characterized in vivo and in vitro and found to have a complete lack of activity in four mutant proteins and residual kinase activity in one. Remarkably, the onset of diabetes was relatively late (30 months) in the patient expressing the partially defective EIF2AK3 mutant and in the patient with no EIF2AK3 involvement (18 months) compared with other patients (<6 months). The patient with no EIF2AK3 involvement did not have any of the other variable clinical manifestations associated with WRS, which supports the idea that the genetic heterogeneity between this variant form of WRS and EIF2AK3 WRS correlates with some clinical heterogeneity.

Original languageEnglish
Pages (from-to)1876-1883
Number of pages8
JournalDiabetes
Volume53
Issue number7
DOIs
StatePublished - Jul 2004

Fingerprint

Genetic Heterogeneity
Mutation
Eukaryotic Initiation Factor-2
Osteochondrodysplasias
Information Storage and Retrieval
Mutant Proteins
Protein Kinases
Wolcott-Rallison syndrome
Phosphotransferases
Insulin
Growth
Genes
Proteins

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Senée, V., Vattem, K. M., Delépine, M., Rainbow, L. A., Haton, C., Lecoq, A., ... Julier, C. (2004). Wolcott-Rallison syndrome: Clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. Diabetes, 53(7), 1876-1883. https://doi.org/10.2337/diabetes.53.7.1876

Wolcott-Rallison syndrome : Clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. / Senée, Valérie; Vattem, Krishna M.; Delépine, Marc; Rainbow, Lynn A.; Haton, Céline; Lecoq, Annick; Shaw, Nick J.; Robert, Jean Jacques; Rooman, Raoul; Diatloff-Zito, Catherine; Michaud, Jacques L.; Bin-Abbas, Bassan; Taha, Doris; Zabel, Bernard; Franceschini, Piergiorgio; Topaloglu, A. Kemal; Lathrop, G. Mark; Barrett, Timothy G.; Nicolino, Marc; Wek, Ronald; Julier, Cécile.

In: Diabetes, Vol. 53, No. 7, 07.2004, p. 1876-1883.

Research output: Contribution to journalArticle

Senée, V, Vattem, KM, Delépine, M, Rainbow, LA, Haton, C, Lecoq, A, Shaw, NJ, Robert, JJ, Rooman, R, Diatloff-Zito, C, Michaud, JL, Bin-Abbas, B, Taha, D, Zabel, B, Franceschini, P, Topaloglu, AK, Lathrop, GM, Barrett, TG, Nicolino, M, Wek, R & Julier, C 2004, 'Wolcott-Rallison syndrome: Clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity', Diabetes, vol. 53, no. 7, pp. 1876-1883. https://doi.org/10.2337/diabetes.53.7.1876
Senée, Valérie ; Vattem, Krishna M. ; Delépine, Marc ; Rainbow, Lynn A. ; Haton, Céline ; Lecoq, Annick ; Shaw, Nick J. ; Robert, Jean Jacques ; Rooman, Raoul ; Diatloff-Zito, Catherine ; Michaud, Jacques L. ; Bin-Abbas, Bassan ; Taha, Doris ; Zabel, Bernard ; Franceschini, Piergiorgio ; Topaloglu, A. Kemal ; Lathrop, G. Mark ; Barrett, Timothy G. ; Nicolino, Marc ; Wek, Ronald ; Julier, Cécile. / Wolcott-Rallison syndrome : Clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. In: Diabetes. 2004 ; Vol. 53, No. 7. pp. 1876-1883.
@article{b8178816836d4cba9c3b0237f112c322,
title = "Wolcott-Rallison syndrome: Clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity",
abstract = "Wolcott-RaRison syndrome (WRS) is a rare autosomal-recessive disorder characterized by the association of permanent neonatal or early-infancy insulin-dependent diabetes, multiple epiphyseal dysplasia and growth retardation, and other variable multisystemic clinical manifestations. Based on genetic studies of two inbred families, we previously identified the gene responsible for this disorder as EIF2AK3, the pancreatic eukaryotic initiation factor 2α (eIF2α) kinase. Here, we have studied 12 families with WRS, totalling 18 cases. With the exception of one case, all patients carried EIF2AK3 mutations resulting in truncated or missense versions of the protein. Exclusion of EIF2AK3 mutations in the one patient case was confirmed by both linkage and sequence data. The activities of missense versions of EIF2AK3 were characterized in vivo and in vitro and found to have a complete lack of activity in four mutant proteins and residual kinase activity in one. Remarkably, the onset of diabetes was relatively late (30 months) in the patient expressing the partially defective EIF2AK3 mutant and in the patient with no EIF2AK3 involvement (18 months) compared with other patients (<6 months). The patient with no EIF2AK3 involvement did not have any of the other variable clinical manifestations associated with WRS, which supports the idea that the genetic heterogeneity between this variant form of WRS and EIF2AK3 WRS correlates with some clinical heterogeneity.",
author = "Val{\'e}rie Sen{\'e}e and Vattem, {Krishna M.} and Marc Del{\'e}pine and Rainbow, {Lynn A.} and C{\'e}line Haton and Annick Lecoq and Shaw, {Nick J.} and Robert, {Jean Jacques} and Raoul Rooman and Catherine Diatloff-Zito and Michaud, {Jacques L.} and Bassan Bin-Abbas and Doris Taha and Bernard Zabel and Piergiorgio Franceschini and Topaloglu, {A. Kemal} and Lathrop, {G. Mark} and Barrett, {Timothy G.} and Marc Nicolino and Ronald Wek and C{\'e}cile Julier",
year = "2004",
month = "7",
doi = "10.2337/diabetes.53.7.1876",
language = "English",
volume = "53",
pages = "1876--1883",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - Wolcott-Rallison syndrome

T2 - Clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity

AU - Senée, Valérie

AU - Vattem, Krishna M.

AU - Delépine, Marc

AU - Rainbow, Lynn A.

AU - Haton, Céline

AU - Lecoq, Annick

AU - Shaw, Nick J.

AU - Robert, Jean Jacques

AU - Rooman, Raoul

AU - Diatloff-Zito, Catherine

AU - Michaud, Jacques L.

AU - Bin-Abbas, Bassan

AU - Taha, Doris

AU - Zabel, Bernard

AU - Franceschini, Piergiorgio

AU - Topaloglu, A. Kemal

AU - Lathrop, G. Mark

AU - Barrett, Timothy G.

AU - Nicolino, Marc

AU - Wek, Ronald

AU - Julier, Cécile

PY - 2004/7

Y1 - 2004/7

N2 - Wolcott-RaRison syndrome (WRS) is a rare autosomal-recessive disorder characterized by the association of permanent neonatal or early-infancy insulin-dependent diabetes, multiple epiphyseal dysplasia and growth retardation, and other variable multisystemic clinical manifestations. Based on genetic studies of two inbred families, we previously identified the gene responsible for this disorder as EIF2AK3, the pancreatic eukaryotic initiation factor 2α (eIF2α) kinase. Here, we have studied 12 families with WRS, totalling 18 cases. With the exception of one case, all patients carried EIF2AK3 mutations resulting in truncated or missense versions of the protein. Exclusion of EIF2AK3 mutations in the one patient case was confirmed by both linkage and sequence data. The activities of missense versions of EIF2AK3 were characterized in vivo and in vitro and found to have a complete lack of activity in four mutant proteins and residual kinase activity in one. Remarkably, the onset of diabetes was relatively late (30 months) in the patient expressing the partially defective EIF2AK3 mutant and in the patient with no EIF2AK3 involvement (18 months) compared with other patients (<6 months). The patient with no EIF2AK3 involvement did not have any of the other variable clinical manifestations associated with WRS, which supports the idea that the genetic heterogeneity between this variant form of WRS and EIF2AK3 WRS correlates with some clinical heterogeneity.

AB - Wolcott-RaRison syndrome (WRS) is a rare autosomal-recessive disorder characterized by the association of permanent neonatal or early-infancy insulin-dependent diabetes, multiple epiphyseal dysplasia and growth retardation, and other variable multisystemic clinical manifestations. Based on genetic studies of two inbred families, we previously identified the gene responsible for this disorder as EIF2AK3, the pancreatic eukaryotic initiation factor 2α (eIF2α) kinase. Here, we have studied 12 families with WRS, totalling 18 cases. With the exception of one case, all patients carried EIF2AK3 mutations resulting in truncated or missense versions of the protein. Exclusion of EIF2AK3 mutations in the one patient case was confirmed by both linkage and sequence data. The activities of missense versions of EIF2AK3 were characterized in vivo and in vitro and found to have a complete lack of activity in four mutant proteins and residual kinase activity in one. Remarkably, the onset of diabetes was relatively late (30 months) in the patient expressing the partially defective EIF2AK3 mutant and in the patient with no EIF2AK3 involvement (18 months) compared with other patients (<6 months). The patient with no EIF2AK3 involvement did not have any of the other variable clinical manifestations associated with WRS, which supports the idea that the genetic heterogeneity between this variant form of WRS and EIF2AK3 WRS correlates with some clinical heterogeneity.

UR - http://www.scopus.com/inward/record.url?scp=3042696843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042696843&partnerID=8YFLogxK

U2 - 10.2337/diabetes.53.7.1876

DO - 10.2337/diabetes.53.7.1876

M3 - Article

C2 - 15220213

AN - SCOPUS:3042696843

VL - 53

SP - 1876

EP - 1883

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7

ER -